New insider activity at Soleno Therapeutics ( (SLNO) ) has taken place on April 1, 2025.
In a series of significant transactions, key executives at Soleno Therapeutics have sold substantial amounts of stock. CEO Anish Bhatnagar led the sales with 523,809 shares sold, amounting to $35,287,354. CFO James Mackaness followed with a sale of 70,000 shares valued at $4,883,084. SVP Global Clinical Operations and Patient Advocacy Kristen Yen sold 73,631 shares for $4,881,445. CCO Manning Meredith sold 37,000 shares, totaling $2,480,110. Director Matthew Pauls and Sr. VP of Clinical Development Michael F. Huang also participated, selling 5,937 and 10,000 shares for $424,792 and $700,300, respectively.
Recent Updates on SLNO stock
Soleno Therapeutics experienced significant stock price movements following the FDA approval of Vykat XR for the treatment of Prader-Willi syndrome, leading to multiple analysts raising their price targets. H.C. Wainwright increased its target due to the higher-than-expected annual list price of Vykat, while Stifel highlighted the drug’s potential as a ‘blockbuster opportunity’ with a projected revenue of $2 billion. Guggenheim’s analyst projected Vykat XR revenues to reach $1.6 billion in the U.S. by 2030. Laidlaw emphasized the lack of competition in the market and the elimination of regulatory risks as reasons for their target increase. Overall, the approval of Vykat XR has positioned Soleno in a favorable market position, driving optimistic revenue forecasts and analyst upgrades.
More about Soleno Therapeutics
YTD Price Performance: 57.49%
Average Trading Volume: 897,004
Technical Sentiment Signal: Sell
Current Market Cap: $3.3B